On February 10, 2023 RhoVac AB reported that on 11 January 2023, an Extraordinary General Meeting was held. The General Meeting resolved to approve the Board of Directors’ proposal to approve the acquisition of CHOSA ApS and change the company’s name to CHOSA Oncology AB. The new name has now been registered by the Swedish Companies Registration Office. The company’s shares will from 15 February 2023 be traded under the new name CHOSA Oncology AB (ticker: CHOSA). The ISIN code will not change and will thus remain SE0007784319. The FISN code will be changed to CHOSAON/SH.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the new name, the company’s website where financial information, regulatory press releases and other investor-related information will be published, will change to www.chosaoncology.com

As previously communicated, the General Meeting also resolved to change the company’s board and management. Peter Buhl Jensen has now taken office as the company’s CEO, and Neil Goldsmith (Chairman), Ulla Hald Buhl, Claus Frisenberg and Ingrid Atteryd Heiman now constitute the company’s Board of Directors, together with the previous board member Lars Hedbys.

(Press release, RhoVac, FEB 10, 2023, View Source [SID1234670221])